Mifepristone, CAS No.: 84371-65-3, in-House Standard

Name: Mifepristone, CAS No.: 84371-65-3, in-House Standard
Brand: Beijing DC-Pharma Co., Ltd.
SKU: 2049119622

Beijing, ChinaBeijing DC-Pharma Co., Ltd.

US$10,000.00

25 kg

Sample price:US$10.00/kg.Request sample

Product profile

Function

Hormones and Regulation of Endocrine Function of Drug

Certification

GMP

Grade Standard

Medicine Grade

Model NO.

0.5-2kg/tin

Type

Chemical Reagent

State

Solid

Volatile

Not Volatile

CAS

84371-65-3

Packaging 1

Bottle

Packaging 2

Bag

Packaging 3

Carton

Market

Foreign

Transport Package

Drum

Specification

25kg/drum

Trademark

Manufacturer

Origin

China

Production Capacity

10tons

Company profile

Years of Export ExperienceHigh Repeat Buyers ChoiceImporters and ExportersMulti-language Pioneer

Beijing DC-Pharma Co., Ltd.

Beijing, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2022-03-25Average Response Time: ≤24hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB

AI-Powered supplier vetting

SummaryBeijing DC-Pharma Co., Ltd. is a China-based limited company in the health and medicine sector, identified as both a trading company and manufacturer/factory. It offers pharmaceutical forms including injections, ampoules, tablets, capsules, and powder, and reports self-operated import and export rights with 41%–50% of sales from exports. Its stated services cover supplier selection, evaluation, production arrangement, transportation coordination, and after-sales support. However, the company has only three employees, one R&D engineer, no new products launched in the past year, no inventory, no overseas warehouse, no overseas agents or branches, and no overseas showroom. Complaint handling and corrective/preventive action procedures exist, but no written records were provided. Audit information identifies TUV Rheinland and an audit validity period from March 24, 2025 to March 23, 2026, but the stated evaluation result is not interpretable as a certification or pass conclusion from the provided data.

Supplier typeThe supplier is identified as a trading company in one record and as both a trading company and manufacturer/factory in another. It is a limited company based in Beijing, China, with health and medicine as its commercial trade sector.

After-Sales capabilityThe supplier states that it provides after-sales support and has procedures for handling customer complaints and corrective/preventive actions. The procedures lack written records, so the existence of a formal process is supported but its demonstrated effectiveness is not.

R&D capabilityThe supplier reports one research and development engineer and no new products launched during the past year. These figures indicate limited demonstrated recent innovation activity.

Customization capabilityThe supplier explicitly reports customization from samples, providing evidence of a sample-based customization service. No broader design or engineering capability is documented.